Every cell in the blood and immune system begins in the bone marrow. Haematopoietic stem cells (HSCs) give rise to all blood cell lineages — red blood cells, platelets, and all immune cells (neutrophils, monocytes, NK cells, B cells, and the T-cell precursors that mature in the thymus). Bone marrow function is the foundational layer of immune competence, and its aging — haematopoietic aging — is a primary driver of immunosenescence.
Bone marrow aging has characteristic features: HSCs accumulate DNA damage and lose self-renewal capacity, the balance of HSC output shifts from lymphoid lineages (immune cells) toward myeloid lineages — producing lymphopenia and myeloid skewing characteristic of aging immune systems. The bone marrow stromal niche deteriorates, and the total HSC pool declines in quality. These changes produce an aging immune system that is simultaneously chronically inflamed (from expanded myeloid output) and immunodeficient (from reduced lymphoid output).
Bonomarlot addresses this foundational source. Bone marrow-derived peptides interact with chromatin in haematopoietic stem cells and their progenitors, activating gene expression programs that maintain HSC self-renewal, support balanced lymphoid and myeloid output, and maintain the bone marrow stromal niche. Where Thymalin and Vilon act on T-cell maturation in the thymus, Bonomarlot acts on the source — the HSCs that generate all immune cell lineages.
How it works
HSC Self-Renewal Gene Expression
Haematopoietic stem cells maintain themselves through self-renewal — dividing while maintaining stem cell identity — and produce committed progenitors through differentiation. Both processes are regulated by transcription factors: Scl/TAL1, GATA-2, Runx1, and others define the HSC transcriptional program. Age-related changes in HSC chromatin architecture impair this program — HSCs lose self-renewal capacity and skew output toward myeloid lineages. Bone marrow-derived Cytomax peptides interact with HSC chromatin, activating gene expression programs that maintain stem cell identity and balanced lineage output.
Lymphoid vs. Myeloid Balance
Myeloid skewing — aged HSCs preferentially producing myeloid cells over lymphoid cells — contributes to the paradox of aging immunity: more inflammatory (from expanded myeloid output) yet more immunodeficient (from reduced adaptive immune cell production). Bonomarlot's gene expression support of HSC self-renewal and balanced lineage commitment is theorised to partly restore more physiological lymphoid:myeloid ratios in HSC output.
The Sequential Immune Bioregulator Model
Bone marrow (Bonomarlot) → HSC output → lymphoid progenitors exit → thymus (Thymalin, Vilon) → T-cell maturation → mature T cells in circulation. Bonomarlot maintains the source; Thymalin and Vilon maintain the maturation site. Running all three provides coverage of the complete T-cell development pathway — addressing immune aging at three sequential levels.
What the research shows
KHAVINSON GROUP DATA PRIMARILY · NO INDEPENDENT WESTERN RCTS
STUDYBulletin of Experimental Biology and Medicine · 2003
Bone marrow peptide bioregulator supports haematopoiesis in aging and post-chemotherapy recovery
Khavinson VKh et al.
Elderly patients with age-related haematopoietic decline and post-chemotherapy patients. Bone marrow Cytomax significantly improved CBC parameters — haemoglobin, lymphocyte counts, platelet recovery. Reduced recovery time post-chemotherapy. Khavinson-group data establishing clinical haematopoietic support pattern.
Short peptides stimulate haematopoietic stem cell proliferation and differentiation
Khavinson VKh, Malinin VV
HSC culture models. Bone marrow-derived short peptides stimulated HSC proliferation, maintained stem cell marker expression, and promoted balanced myeloid/lymphoid progenitor output. Establishes the direct HSC mechanism in culture.
✓Logical complement to Thymalin/Vilon in the immune bioregulator sequence — sequential organ targeting
?UNCERTAIN
?Independent Western validation of haematological improvements
?Whether myeloid skewing reversal occurs meaningfully in humans
?Optimal timing and frequency for immune aging prevention in healthy adults
?Whether post-chemotherapy haematopoietic effects translate across cancer types and treatment regimens
?Comparison with haematopoietic growth factors (G-CSF, EPO) in clinical settings
Community knowledge
Bonomarlot is used primarily by the more research-oriented longevity biohacker who has gone deep into the Khavinson immune system approach. The complete immune bioregulator stack — Bonomarlot + Thymalin + Vilon — is the most comprehensive immune aging approach in the series, addressing bone marrow source, thymic maturation, and thymic signalling at all three sequential levels.
—Post-chemotherapy recovery: the most clinically specific community use — cancer patients who have completed chemotherapy use Bonomarlot for haematopoietic recovery; the post-chemotherapy Khavinson data is the most compelling clinical evidence
—Blood count improvement: users tracking CBC report improved lymphocyte counts and haemoglobin during and after courses — consistent with the haematopoietic support mechanism
—Energy improvement: improved haematopoiesis → improved red blood cell production → improved oxygen delivery → improved energy; consistent reports on this pathway
—Staggered with Thymalin: users run Bonomarlot (months 1 and 7) and Thymalin (months 4 and 10) in alternating courses for continuous immune bioregulator coverage throughout the year
AI RESEARCHER PREVIEW
I want to build a complete immune bioregulator stack. How do Bonomarlot, Thymalin, and Vilon work together?
The three compounds address immune aging at sequential biological levels. Month 1 and 7: Bonomarlot oral course (10 days) — bone marrow HSC source. Month 4 and 10: Thymalin oral course (10 days) — thymic T-cell maturation. Months 2 and 8: Vilon injectable KE Cytogen course (10 days, 500 mcg/day SC) — thymic signalling layer between Thymalin courses. This sequencing provides immune bioregulator coverage at every level — bone marrow output, thymic maturation, and thymic signalling — throughout the year without overlapping courses. What to monitor: CBC with lymphocyte differential at baseline and after your first Bonomarlot course. Focus on lymphocyte count (immune competence) and haemoglobin (red blood cell production). A neutrophil:lymphocyte ratio above 3 is a marker of immunosenescence — if yours is elevated, this is a particularly relevant stack. For post-chemotherapy use specifically: start Bonomarlot 2 weeks after completing chemotherapy, track CBC weekly, repeat at 3 months if recovery is incomplete.
CONTINUE IN THE APP
Open PepperLedger to track your Bonomarlot protocol →
Free to join. The Researcher understands the full Khavinson immune bioregulator system and can help you design a complete immune aging protocol.
Free to join · No credit card · 23-day Pro trial included